The shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has been pegged with a rating of Buy by H.C. Wainwright in its latest research note that was published on August 1st, 2019. The research company has also assigned a $16 price target. H.C. Wainwright wasn’t the only research firm that published a report of AMAG Pharmaceuticals, Inc., with other equities research analysts also giving their opinion on the stock. Barclays advised investors in its research note published on June 11th, 2019, to Overweight the AMAG stock while also putting a $19 price target. The stock had earned Hold rating from SunTrust when it published its report on March 20th, 2019. The stock was given Buy rating by B. Riley FBR in its report released on December 14th, 2018, the day when the price target on the stock was placed at $20.50. JP Morgan was of a view that AMAG is Underweight in its latest report on November 6th, 2018. Janney thinks that AMAG is worth Neutral rating. This was contained in the firm’s report on June 15th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 7 believe it has the potential for further growth, thus rating it as Hold while 0 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $11.25. The price of the stock the last time has raised by 51.10% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 52.69.
The shares of the company dipped by -3.74% during the trading session on Thursday, reaching a low of $10.17 while ending the day at $10.29. During the trading session, a total of 1.29 million shares were traded which represents a -4.17% decline from the average session volume which is 1.24M shares. AMAG had ended its last session trading at 10.69. AMAG Pharmaceuticals, Inc. currently has a market cap of $348.83M while its P/E earnings growth sits at 0.96, with a beta of 0.07. AMAG Pharmaceuticals, Inc. debt-to-equity ratio currently stands at 0.54, while its quick ratio hovers at 1.50. AMAG 52-week low price stands at $6.81 while its 52-week high price is $25.20.
The company in its last quarterly report recorded -$0.87 earnings per share which is below the -$0.57 predicted by most analysts. The AMAG Pharmaceuticals, Inc. generated $78.11 million in revenue during the last quarter, which is slightly lower than the $91.77 million predicted by analysts. In the second quarter last year, the firm recorded -$1.15 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -32.18%. AMAG Pharmaceuticals, Inc. has the potential to record -9.59 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Goldman published a research note on May 3rd, 2019 where it informed investors and clients that YETI Holdings, Inc. (NYSE:YETI) is now rated as Neutral. Their price target on the stock stands at $33. Barclays also rated YETI as Initiated on June 11th, 2019, with its price target of $19 suggesting that YETI could surge by 23.02% from its current share price. Even though the stock has been trading at $28.20/share, analysts expect it to surge higher by 3.05% to reach $37.75/share. It started the day trading at $29.43 and traded between $28.35 and $29.06 throughout the trading session.
A look at its technical shows that YETI’s 50-day SMA is 30.61 while its 200-day SMA stands at 24.70. The stock has a high of $38.11 for the year while the low is $12.40. The company’s P/E ratio currently sits at 37.07, while the P/B ratio is 38.24. At the moment, only of YETI Holdings, Inc. shares were sold short. The company’s average trading volume currently stands at 1.58M shares, which means that the short-interest ratio is just 10.40 days. Over the past seven days, the company moved, with its shift of 7.63%. Looking further, the stock has raised 6.10% over the past 90 days while it gained 18.76% over the last six months.
The Vanguard Group Inc meanwhile bought more YETI shares in the recently filed quarter, changing its stake to $142,310,881 worth of shares. Lord Abbett Co LLC followed the path by decreasing its YETI portfolio by -0.20% in the quarter. This means that Lord Abbett Co LLC sold -7,464 shares in the last quarter and now controls 3,766,482 shares of the YETI stock, with the valuation hitting $130,922,914.
Similarly, BlackRock Fund Advisors increased its YETI Holdings, Inc. shares by +82.70% during the recently filed quarter. Following these latest developments, around 1.00% of YETI Holdings, Inc. stocks are owned by institutional investors and hedge funds.